Evidence map›Paper›PMID 28533686›Full record

ArticleTherapeutics and clinical risk management2017

Misoprostol for miscarriage management in a woman with previous five cesarean deliveries: a case report and literature review.

Doua AlSaad, Sawsan Alobaidly, Palli Abdulrouf, Binny Thomas, Afif Ahmed, Moza AlHail

Open access · goldAbstract readCase Reports
In one paragraph

Article in Therapeutics and clinical risk management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Doua AlSaadDepartment of Pharmacy, Women's Hospital, Hamad Medical Corporation, Doha, Qatar.
Sawsan AlobaidlyDepartment of Obstetrics and Gynecology, Women's Hospital.
Palli AbdulroufDepartment of Pharmacy, Women's Hospital, Hamad Medical Corporation, Doha, Qatar.
Binny ThomasClinical Support Service Unit, Hamad Medical Corporation, Doha, Qatar.
Afif AhmedDepartment of Pharmacy, Women's Hospital, Hamad Medical Corporation, Doha, Qatar.
Moza AlHailDepartment of Pharmacy, Women's Hospital, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QAUniversity of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMisoprostol is an effective medical method for the management of pregnancy loss. However, data on its efficacy and safety in women with previous cesarean deliveries are limited. CASE PRESENTATION: We report a 36-year-old patient, gravida 11 para 6, with a diagnosis of missed miscarriage at 15 weeks of gestation. The patient had a significant obstetric history of previous five cesarean deliveries and uterine rupture. Following patient counseling about the medical and surgical options of managing her miscarriage, the patient opted for medical method. Low-dose misoprostol of 100 µg was inserted vaginally and repeated again after 6 hours. The patient had an uneventful complete miscarriage following the second dose of misoprostol. No uterine rupture, no extra vaginal bleeding, and no blood transfusion were observed.

conclusionWe conclude that adopting a low-dose misoprostol protocol could be potentially safe and effective in managing second trimester missed miscarriage in women with repeated cesarean deliveries and/or uterine rupture history. Further studies are needed to confirm these results.

Indexed as

abortioncesarean sectionmiscarriagemisoprostolprostaglandin E1second trimesteruterine rupture

Identifiers

PMID28533686
PMCPMC5431700
OpenAlexW2612206107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.